Hanmi Pharmaceutical is at the forefront of innovative drug development, leveraging advanced technologies such as long-acting platform technology and bispecific antibody platform technology. The long-acting platform technology focuses on creating medications that provide extended therapeutic effects, particularly in treating metabolic disorders like metabolic dysfunction-associated steatohepatitis (MASH). This technology enables the development of multi-targeted therapies, such as efocipegtrutide, which acts as a triple agonist for glucagon, gastric inhibitory peptide (GIP), and glucagon-like peptide-1 (GLP-1). This approach aims to enhance therapeutic efficacy by simultaneously addressing multiple pathways involved in disease progression, thereby improving patient outcomes.

In addition to its long-acting platform, Hanmi is also pioneering bispecific antibody technology, which allows for the creation of antibodies that can simultaneously target two different antigens. This innovative approach is particularly beneficial in oncology, where it can enhance the immune response against cancer cells. The company’s commitment to research and development is further exemplified by its focus on open innovation, fostering collaborations with various stakeholders to accelerate the discovery and development of new therapeutic solutions. Through these technologies, Hanmi Pharmaceutical aims to address unmet medical needs and improve the quality of life for patients worldwide.

South Korea

Hanmi Pharmaceutical

Antibodies

Biologics

Generics

Small Molecule Pharmaceuticals

Contract Manufacturing

Contract Research

Therapeutic

Vendor

Hanmi Pharmaceutical

Company Details